The U. S. Supreme Court decided unanimously that health maintenance organizations cannot be sued for providing physicians with financial incentives to keep costs down. The case, Herdrich v. Pegram, involved a woman who complained of abdominal pain only to be told that she would have to wait eight days for an ultrasound. Her appendix subsequently ruptured, causing peritonitis. Upon recovery, she sued her HMO in state court, claiming that they had violated their fiduciary duty under the Employee Retirement Income Security Act.
The U. S. Supreme Court decided unanimously that health maintenance organizations cannot be sued for providing physicians with financial incentives to keep costs down. The case, Herdrich v. Pegram, involved a woman who complained of abdominal pain only to be told that she would have to wait eight days for an ultrasound. Her appendix subsequently ruptured, causing peritonitis. Upon recovery, she sued her HMO in state court, claiming that they had violated their fiduciary duty under the Employee Retirement Income Security Act.
The Supreme Court held that the plaintiff failed to state an ERISA claim, but left HMOs vulnerable to lawsuits in the state courts.
Karen Igniani, president of the American Association of Health Plans, called the decision a "resounding victory for maintaining affordable care" and an "equally resounding defeat for suit-happy trial lawyers."
"The Court's decision today validates the principle that the legal system is not the place to make healthcare work," said Igniani. "Rather, we should all work together to make sure that patients have a way to quickly and fairly resolve disputes when they disagree with health plan coverage decisions. We will continue to advocate strongly for a patient's right to an outside, independent review."
Added Chip Kahn, president of the Health Insurance Association of America, "The Herdrich decision makes clear that a health plan's use of incentive payments and other devices to encourage affordable healthcare is not a violation of the Employee Retirement Income Security Act. In so ruling, the high court dealt a body blow against one of the key tenets of several baseless class-action suits launched recently against many health plans. It is our hope that the trial bar will heed the message of Herdrich and recognize that consumers are ill-served by expensive litigation that would drive up coverage costs and dramatically increase the number of uninsured Americans." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.